The oligopeptide transporter 2-mediated reabsorption of entecavir in rat kidney.

Eur J Pharm Sci

Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, China; Provincial Key Laboratory for Pharmacokinetics and Transport, Liaoning, Dalian Medical University, China. Electronic address:

Published: February 2014

We investigated whether entecavir is a substrate of the oligopeptide transporter 2 (PEPT2) and whether reabsorption of entecavir is mediated by PEPT2 as well as what is the contribution of PEPT2 to entecavir reabsorption during urinary excretion. Entecavir uptake in transfected cells and rat kidney slices, changes in urine entecavir concentrations following isolated kidney perfusion and in vivo entecavir plasma and urine concentrations were determined with LC-MS/MS. In hPEPT2-HELA cells, entecavir uptake was significantly higher compared to vector-HELA cells and was sharply inhibited by Gly-sar and JBP485, and there were two distinct transport systems. The Km and Vmax of entecavir were 427 (μM) and 1.60 (nmol/mg protein/30s) (low-affinity, high-velocity system) and 24.0 (μM) and 0.296 (nmol/mg protein/30s) (high-affinity, low-velocity system). In rat kidney slices, uptake of entecavir was not markedly inhibited by Gly-sar. In isolated kidney perfusion experiments, entecavir cumulative urinary excretion was statistically significant at 45 and 60 min. CLR(4 °C), CLR(37 °C Control) and CLR(37°C Experiment) were 12.6, 27.6 and 36 (ml/min/kg), respectively. CLTS and TR rate (for PEPT2) were 25.3 and 9.4 (ml/min/kg). In vivo, the cumulative urinary excretion of entecavir had statistical significance at 3 and 4h with CLR(Control) and CLR(Experiment) values of 31 and 42 (ml/min/kg), respectively. The CLTS and TR rate (for PEPT2) were 32 and 11.6 (ml/min/kg), respectively. The present study demonstrated that entecavir is a substrate of PEPT2. Moreover, reabsorption of entecavir is mediated by PEPT2, and 25% of urinary entecavir is reabsorbed by PEPT2.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejps.2013.10.010DOI Listing

Publication Analysis

Top Keywords

entecavir
15
reabsorption entecavir
12
rat kidney
12
urinary excretion
12
oligopeptide transporter
8
entecavir substrate
8
pept2
8
pept2 reabsorption
8
entecavir mediated
8
mediated pept2
8

Similar Publications

Unlabelled: Hepatitis B infection remains a significant global health concern, with hepatitis D co-infection observed in approximately 5% of the patients. Treatment options for hepatitis D are currently limited, with most therapies awaiting approval by the FDA. However, there is a lack of comprehensive data on the prevalence and clinical presentation of patients with hepatitis B and D coinfection, particularly in Pakistan.

View Article and Find Full Text PDF

Few cases of tenofovir resistance have been reported, and the appropriate treatment for such cases remains unclear. We aimed to share a case of a chronic hepatitis B mono-infected patient with potential tenofovir resistance who required combined lamivudine and tenofovir therapy to achieve adequate viral suppression. The patient's viral load (plasma) was monitored using the cobas® hepatitis B virus Test on the cobas® 6800 system.

View Article and Find Full Text PDF

Rationale: Mass vaccination, low cost of immunoglobulins, and new drugs led to the emergence of new, unusual patterns of hepatitis B serum markers. This study reported a rare case of hepatitis B with all 5 positive serum markers, including HBsAg, HBsAb, HBeAg, HBeAb, and HBcAb.

Patient Concerns: A 30-year-old female patient was admitted due to abnormal liver function.

View Article and Find Full Text PDF

Rationale: Current research on antiviral treatment in children is relatively limited, especially in children under 1 year old.

Patient Concerns: Liu XX, an 8-month-old infant (case number: 3001120473), presented to the hospital in August 2016 with a chief complaint of being "hepatitis B surface antigen positive for 8 months and experiencing abnormal liver function for 5 months."

Diagnoses: The patient was diagnosed as chronic hepatitis B cirrhosis (G3S3-4) with active compensatory phase.

View Article and Find Full Text PDF

Tenofovir vs. Entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma patients after liver resection: the role of HBsAg levels.

Clin Transl Gastroenterol

January 2025

Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.

Background: Our study aimed to explore whether hepatitis B surface antigen (HBsAg) levels affected the role of nucleot(s)ide analog treatment (entecavir (ETV) and tenofovir (TDF)) in improving the prognosis of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) patients after liver resection.

Methods: A total of 865 HBV-related HCC patients after hepatectomy treated with TDF or ETV were included in our study. Patients were divided into the high HBsAg cohort (n=681) and the low HBsAg cohort (n=184).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!